Christoph Haarburger

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

Preventing blindness and vision impairment.

ARISTRA ist das Radiologie-Netzwerk für Ärzt:innen und Patient:innen. ARISTRA bedeutet hochspezialisierte Radiologie. Insbesondere im Bereich der MRT-Diagnostik verbessern wir so die medizinische Versorgung vor Ort. Gemeinsam mit unseren Partnerpraxen in Deutschland und der Schweiz. Die Zusammenarbeit mit internationalen Expert:innen erlaubt es uns, unseren Patient:innen flächendeckend Spezialwissen kombiniert mit modernster Technologie zu bieten.